Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39110
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchuler, M. H. H.-
dc.contributor.authorCUPPENS, Kristof-
dc.contributor.authorPloenes, T.-
dc.contributor.authorVanbockrijck, M.-
dc.contributor.authorWiesweg, M.-
dc.contributor.authorDarwiche, K.-
dc.contributor.authorSchramm, A.-
dc.contributor.authorMAES, Brigitte-
dc.contributor.authorHegedus, B.-
dc.contributor.authorSchildhaus, H-U.-
dc.contributor.authorHautzel, H.-
dc.contributor.authorTheegarten, D.-
dc.contributor.authorBaas, P.-
dc.contributor.authorHartemink, K.-
dc.contributor.authorDu Pont, B.-
dc.contributor.authorAigner, C.-
dc.date.accessioned2023-01-03T10:25:22Z-
dc.date.available2023-01-03T10:25:22Z-
dc.date.issued2022-
dc.date.submitted2022-12-23T13:49:52Z-
dc.identifier.citationANNALS OF ONCOLOGY, 33 (7) , p. S1404-
dc.identifier.urihttp://hdl.handle.net/1942/39110-
dc.description.abstractBackground: Preoperative immune checkpoint inhibitor therapy (PICIT) is a promising approach in curative treatment of non-small-cell lung cancer (NSCLC). This study explores the feasibility and efficacy of targeting PD-1 and LAG-3 prior to resection.-
dc.description.sponsorshipBristol Myers Squibb-
dc.language.isoen-
dc.publisherELSEVIER-
dc.titleA randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 09-13, 2022-
local.bibliographicCitation.conferencenameAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO)-
local.bibliographicCitation.conferenceplaceELECTR NETWORK-
dc.identifier.issue7-
dc.identifier.spageS1404-
dc.identifier.volume33-
local.format.pages1-
local.bibliographicCitation.jcatM-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrLBA37-
dc.identifier.doi10.1016/j.annonc.2022.08.034-
dc.identifier.isi000866211602444-
local.provider.typewosris-
local.description.affiliation[Schuler, M. H. H.; Wiesweg, M.; Schramm, A.] Univ Hosp Essen, Dept Med Oncol, Essen, Germany.-
local.description.affiliation[Cuppens, K.] Jessa Hosp, Dept Pulmonol & Thorac Oncol, Hasselt, Belgium.-
local.description.affiliation[Ploenes, T.; Theegarten, D.; Aigner, C.] Univ Med Essen, Ruhrlandklin, Dept Thorac Surg & Endoscopy, Essen, Germany.-
local.description.affiliation[Vanbockrijck, M.] Jessa Hosp, Dept Pathol, Hasselt, Belgium.-
local.description.affiliation[Darwiche, K.] Univ Med Essen, Ruhrlandklin, Dept Pulm Med, Essen, Germany.-
local.description.affiliation[Maes, B.] Jessa Hosp, Dept Lab Med, Hasselt, Belgium.-
local.description.affiliation[Hegedus, B.] Univ Med Essen, Ruhrlandklin, Dept Thorac Surg & Endoscopy, Essen, Germany.-
local.description.affiliation[Schildhaus, H-U.] Univ Hosp Essen, Inst Pathol, Essen, Germany.-
local.description.affiliation[Hautzel, H.] Univ Hosp Essen, Dept Nucl Med, Essen, Germany.-
local.description.affiliation[Baas, P.] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Lung Canc Ctr & Thorac Oncol, Amsterdam, Netherlands.-
local.description.affiliation[Hartemink, K.] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands.-
local.description.affiliation[Du Pont, B.] Jessa Hosp, Dept Thorac & Vasc Surg, Hasselt, Belgium.-
local.uhasselt.internationalyes-
item.accessRightsRestricted Access-
item.fullcitationSchuler, M. H. H.; CUPPENS, Kristof; Ploenes, T.; Vanbockrijck, M.; Wiesweg, M.; Darwiche, K.; Schramm, A.; MAES, Brigitte; Hegedus, B.; Schildhaus, H-U.; Hautzel, H.; Theegarten, D.; Baas, P.; Hartemink, K.; Du Pont, B. & Aigner, C. (2022) A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung). In: ANNALS OF ONCOLOGY, 33 (7) , p. S1404.-
item.contributorSchuler, M. H. H.-
item.contributorCUPPENS, Kristof-
item.contributorPloenes, T.-
item.contributorVanbockrijck, M.-
item.contributorWiesweg, M.-
item.contributorDarwiche, K.-
item.contributorSchramm, A.-
item.contributorMAES, Brigitte-
item.contributorHegedus, B.-
item.contributorSchildhaus, H-U.-
item.contributorHautzel, H.-
item.contributorTheegarten, D.-
item.contributorBaas, P.-
item.contributorHartemink, K.-
item.contributorDu Pont, B.-
item.contributorAigner, C.-
item.fulltextWith Fulltext-
crisitem.journal.issn0923-7534-
crisitem.journal.eissn1569-8041-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung).pdf
  Restricted Access		Published version85.97 kBAdobe PDFView/Open    Request a copy
Show simple item record

WEB OF SCIENCETM
Citations

12
checked on Sep 2, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.